IO Biotech Completes Oversubscribed EUR 127 Million Series B Financing to Accelerate Clinical Programs in Oncology
(2) COPENHAGEN, Denmark, Jan. 13, 2021 /PRNewswire/ -- IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating anti-cancer therapies based on its proprietary T-win technology, announced today that it has raised EUR 127 million in Series B financing. The financing round was led by HBM Healthcare Investments, and other new investors joining the round included Vivo Capital, Kurma Partners, Avoro Capital, RA Capital Management, Samsara Biocapital, Idinvest Partners 1, PFM Health Sciences, Soleus Capital, Eir Ventures and Serrado Capital, with the participation o...
Source: finanznachrichten.de